v3.25.3

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Name:	ffd_TtlFeeAmt
Namespace Prefix:	ffd_
Data Type:	ffd:nonNegative1TMonetary2ItemType
Balance Type:	na
Period Type:	duration

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Name:	ffd_TtlOfferingAmt
Namespace Prefix:	ffd_
Data Type:	ffd:nonNegative1TMonetary2ItemType
Balance Type:	na
Period Type:	duration

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Name:	ffd_TtlOffsetAmt
Namespace Prefix:	ffd_
Data Type:	ffd:nonNegative1TMonetary2ItemType
Balance Type:	na
Period Type:	duration

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Name:	ffd_TtlPrevslyPdAmt
Namespace Prefix:	ffd_
Data Type:	ffd:nonNegative1TMonetary2ItemType
Balance Type:	na
Period Type:	duration

GT Biopharma, Inc. S-1